Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.

Wenmin Chen,Jietao Lin,Ting Yang, Ze Xin Zhang,Lanting Tao,Zhiwei Xiao,Hanrui Chen,Xiangjun Qi,Lingling Sun,Yang Cao,Lizhu Lin

Integrative Cancer Therapies（2023）

引用 0|浏览5

暂无评分

摘要

The Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine approved the study protocol (approval no.: K2020151, 2021/08/19). The study will also be supervised and managed by the Ethics Committee.

查看译文

关键词

NSCLC,TCM,YFSJF,anloinib,combination therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要